𝔖 Bobbio Scriptorium
✦   LIBER   ✦

New agents in acute myeloid leukemia: Beyond cytarabine and anthracyclines

✍ Scribed by Amir T. Fathi; Judith E. Karp

Book ID
107546695
Publisher
Current Science Inc.
Year
2009
Tongue
English
Weight
324 KB
Volume
11
Category
Article
ISSN
1523-3790

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

New agents in acute myeloid leukemia and
New agents in acute myeloid leukemia and other myeloid disorders
✍ Farhad Ravandi; Hagop Kantarjian; Francis Giles; Jorge Cortes πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 136 KB

## Abstract Over the past several decades, improvements in chemotherapeutic agents and supportive care have resulted in significant progress in treating patients with acute myeloid leukemia (AML). More recently, advances in understanding the biology of AML have resulted in the identification of new

Arsenic trioxide and low-dose cytarabine
Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia
✍ Gail J. Roboz; Ellen K. Ritchie; Tania Curcio; Juliette Provenzano; Rebecca Carl πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 135 KB

## Abstract ## BACKGROUND. Acute myeloid leukemia (AML) carries a dismal prognosis in older patients. In this study, the authors evaluated the safety and efficacy of arsenic trioxide combined with low‐dose cytarabine in untreated patients aged β‰₯60 years with AML. ## METHODS. In a phase 1/2 desig